**Supplemental Table S1.** Study Attrition

|  |  |  |
| --- | --- | --- |
| **Inclusion** | **iGlarLixi** | **Basal-Bolus Insulin** |
| ***n*** | **%** | ***n*** | **%** |
| Patients meeting cohort entry criteria | 13,346 |  | 455,230 |  |
| Excluded due to insufficient enrollment | 9,681 | 72.5 | 269,718 | 59.2 |
| Excluded based on previous iGlarLixi fill since 1/1/2017 | 9,681 | 100 | 197,356 | 73.2 |
| Excluded based on previous iGlarLixi fill during baseline | 9,681 | 100 | 161,362 | 81.8 |
| Excluded based on previous bolus fill during baseline | 7,730 | 79.8 | 160,438 | 99.4 |
| Excluded based on previous bolus fill since 1/1/2017 | 7,259 | 93.9 | 160,280 | 99.9 |
| Excluded based on previous premix fill during baseline | 6,971 | 96.0 | 149,857 | 93.5 |
| Excluded based on previous premix fill since 1/1/2017 | 6,863 | 98.5 | 148,141 | 98.9 |
| Excluded based on no 1 IP or 2 OP type 2 diabetes diagnosis during baseline | 6,167 | 89.9 | 116,556 | 78.7 |
| Excluded based on no use of basal insulin during baseline | 2,788 | **45.2** | 84,502 | 72.5 |
| Excluded based on <18 years of age on cohort entry | 2,788 | 100 | 84,371 | 99.8 |
| Excluded based on age missing on cohort entry | 2,788 | 100 | 84,370 | 100 |
| Excluded based on no valid A1C during baseline | 1,284 | **46.1** | 30,146 | 35.7 |
| Excluded based on type 1 diabetes during study period | 1,138 | 88.6 | 23,654 | 78.5 |
| Excluded based on secondary diabetes diagnosis during study period | 1,090 | 95.8 | 21,671 | 91.6 |
| Excluded based on pregnancy-related diagnoses during study period | 1,088 | 99.8 | 21,274 | 98.2 |
| Excluded based on gestational diabetes diagnosis during study period | 1,088 | 100 | 21,274 | 100 |
| Excluded based on polycystic ovarian syndrome diagnosis during study period | 1,082 | 99.4 | 21,208 | 99.7 |
| Total  | **1,082** |  | **21,208** |  |